遼寧成大(600739.SH):就掛牌轉讓成大方圓股權 與國大藥房簽訂產權交易合同
格隆匯 7 月 24日丨遼寧成大(600739.SH)公佈,公司第九屆董事會第十九次(臨時)會議、2020年第二次臨時股東大會,審議通過了《關於公司掛牌轉讓成大方圓醫藥集團有限公司全部股權的議案》等相關議案,決定轉讓所持有的成大方圓醫藥集團有限公司(“成大方圓”、“標的企業”)全部股權。該方案已經遼寧省國有資產經營有限公司審批通過。
公司通過大連產權交易所連續公開掛牌轉讓成大方圓股權,掛牌期內,徵集到意向受讓方國藥控股國大藥房有限公司(“國大藥房”)。2020年7月24日,大連產權交易所確認了公司與國大藥房簽訂的《產權交易合同》,交易價款為人民幣18.6億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.